BioRestorative Therapies (BRTX) announced the hiring of Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025. In his role, Mr. Lipkins will be responsible for sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative domestically and internationally, as well as providing new product and sales expertise to the Company. Lipkins has an accomplished record of business development success within the healthcare industry. He brings over 30 years of venture capital, finance, and sales experience, with deep expertise in the anti-aging and wellness sectors. His extensive work and network in stem cells, regenerative medicine, and tissue banking have helped drive the development of a number of cutting-edge therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRTX:
- Positive Outlook for BioRestorative Therapies: Advancements in Clinical Trials and Financial Stability Drive Buy Rating
- BioRestorative Therapies’ Earnings Call: Progress Amid Challenges
- BioRestorative Therapies Reports Q1 2025 Results and Updates
- BioRestorative Therapies Issues Regulation FD Disclosure
- BioRestorative Therapies announces preliminary data from BRTX-100 trial in cLDD